Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Combination Treatment of Binimetinib and Nivolumab for Advanced V600BRAF Wildtype Melanoma with Innate Anti-PD-1 Resistance

NCT04375527 is registered in ClinicalTrials.gov with Jonsson Comprehensive Cancer Center as lead sponsor.

NCT NCT04375527
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04375527 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Combination Treatment of Binimetinib and Nivolumab for Advanced V600BRAF Wildtype Melanoma with Innate Anti-PD-1 Resistance
Lead sponsor
Jonsson Comprehensive Cancer Center
Phase
Phase 2
Overall status
Terminated
Start date
December 3, 2020
Completion date
November 22, 2024
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage iii cutaneous melanoma ajcc v8, clinical stage iv cutaneous melanoma ajcc v8, locally advanced cutaneous melanoma, metastatic cutaneous melanoma, pathologic stage iii cutaneous melanoma ajcc v8, pathologic stage iiia cutaneous melanoma ajcc v8, pathologic stage iiib cutaneous melanoma ajcc v8, pathologic stage iiic cutaneous melanoma ajcc v8, pathologic stage iiid cutaneous melanoma ajcc v8, pathologic stage iv cutaneous melanoma ajcc v8, unresectable cutaneous melanoma